Roche FoundationOne Liquid
Roche has globally launched FoundationOne Liquid, a liquid biopsy test that can identify 70 of the most commonly mutated genes in solid tumors, as well as microsatellite instability. The test complements FoundationOne CDx, the company's tissue-based genomic profiling test, and is different from FoundationAct, the firm's first liquid biopsy assay, which analyzed 62 genes and did not report MSI.
Sysmex Inostics OncoBeam EGFR Kit V2
Sysmex Inostics, a subsidiary of Sysmex, has launched the OncoBeam EGFR Kit V2 for research use only in Europe and Asia. Replacing the firm's EGFR V1 kit, the V2 kit features workflow improvements, such as minimizing hands-on time and increasing efficiency. In addition, the kit covers substantially more mutations in the EGFR gene than its predecessor.
Sysmex's tool employs the firm's BEAMing technology to detect 36 cancer-relevant EGFR mutations present in ctDNA extracted from plasma, including sensitizing mutations like exon 19 deletions and L848R, as well as the T790M resistance mutation and multiple C797S variants. The assay combines emulsion-based PCR with flow cytometry to provide sensitive detection of rare mutant molecules. According to the firm, the assay requires a minimum of 2 ml of plasma to quickly deliver a comprehensive view of EGFR mutation status across all tumor cells.
Mawi DNA Technologies iSWAB Cell Stabilization Line
Mawi DNA Technologies has launched the iSWAB-Cells platform. The system is designed to collect and stabilize intact cells for up to four weeks at room temperature, allowing researchers to perform multiple omics analyses from a single sample. The family of products includes the iSWAB noninvasive buccal cell collection system as well as a separate stabilization buffer for cells within different biological matrices.
For more new products and services, please visit the New Products page on our website.